The imported shingles vaccine is in short supply. This is because MSD's Zostavax has been out of stock for a while and the introduction of Shingrix, which was approved last year, continues to be delayed. According to the pharmaceutical industry on the 31st, Zostavax has been out of stock for about two months. MSD, which announced the news of its out of stock at the end of June, said it would resume supply at the end of July, but it is expected that it will not be able to supply again until September due to the postponement of the schedule. Zostavax was sold out in some regions due to a sudden increase in demand in 2020. In this regard, an MSD official said, "Zostavax is experiencing a short-term out of stock, and we